



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Insulin efsitora alfa

Cat. No.:	HY-P99665
CAS No.:	2131038-11-2
Target:	Insulin Receptor
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes ^[1] .
In Vitro	Insulin efsitora alfa (0.01-100 nM) stimulates human insulin receptor isoform A (hIR-A) and human insulin receptor isoform B (hIR-B) phosphorylation in HEK293 cells with EC ₅₀ values of 4241 nM and 391 nM, respectively ^[2] . Insulin efsitora alfa (20 µM; 30 min) significantly promotes the dephosphorylation of hIR-A and hIR-B ^[2] . Insulin efsitora alfa stimulates the lipogenesis of 3T3-L1 adipocytes and the proliferation of SAOS-2 and H4IIE cells with EC ₅₀ values of 19 nM, 134 nM and 20 nM, respectively ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Insulin efsitora alfa (3, 10 and 30 nmol/kg; s.c.; single dose) significantly reduces blood glucose in diabetes rats treated with Streptozotocin (HY-13753) ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Heise T, et al. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. *Diabetes Obes Metab.* 2023 Apr;25(4):1080-1090.

[2]. Moyers JS, et al. Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein. *J Pharmacol Exp Ther.* 2022 Sep;382(3):346-355.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA